FEIM · XBRL financial data

Frequency Electronics financial statements, every fiscal year

The same tables from 8 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (FEIM's year ends in late April)

In thousands of dollars	FY 2021Apr 30, 2021	FY 2022Apr 30, 2022	FY 2023Apr 30, 2023	FY 2024Apr 30, 2024	FY 2025Apr 30, 2025	FY 2026Apr 30, 2026
Revenue	54,254	48,296	40,777	55,274	69,811	63,227
Cost of revenue	37,333	39,697	32,928	36,691	39,714	44,831
Gross profit	16,921	8,599	7,849	18,583	30,097	18,396
Research and development	4,690	4,975	3,149	3,380	6,076	5,994
Selling, general and administrative	13,189	11,662	9,372	10,184	12,289	15,403
General and administrative	—	—	—	—	—	400
Operating income (loss)	(958)	(8,038)	(4,672)	5,019	11,732	(3,001)
Interest income	458	199	—	—	—	—
Interest expense	127	77	156	109	104	87
Other income (expense)	1,103	160	7	(7)	(3)	(493)
Income tax expense (benefit)	(204)	1	74	(130)	(11,542)	(2,005)
Net income (loss)	680	(8,663)	(5,501)	5,594	23,686	(903)
Earnings per share, basic USD per share	—	—	—	0.59	2.46	(0.09)
Earnings per share, diluted USD per share	—	—	—	0.59	2.46	(0.09)
Weighted average shares, basic thousands of shares	9,178	9,266	9,337	9,431	9,612	9,783
Weighted average shares, diluted thousands of shares	9,248	9,266	9,337	9,431	9,615	9,783

Fiscal years (FEIM's year ends in late April)

In thousands of dollars	FY 2021Apr 30, 2021	FY 2022Apr 30, 2022	FY 2023Apr 30, 2023	FY 2024Apr 30, 2024	FY 2025Apr 30, 2025	FY 2026Apr 30, 2026
Cash and cash equivalents	9,807	11,561	12,049	18,320	4,720	1,603
Marketable securities	10,313	9,964	0	—	—	—
Accounts receivable	5,515	4,291	4,622	4,614	5,914	4,740
Inventory	19,661	19,906	20,526	23,431	23,487	22,618
Prepaid and other current assets	991	1,162	1,071	1,196	1,071	1,517
Total current assets	48,679	56,010	48,307	58,121	53,106	47,976
Property and equipment, net	9,612	8,564	7,093	6,438	6,188	7,105
Right-of-use asset	9,773	8,805	7,382	6,036	8,659	7,409
Goodwill	—	—	617	617	617	218
Total assets	86,016	84,760	74,496	83,253	93,737	90,706
Accounts payable	—	—	—	2,348	—	—
Accrued liabilities	5,245	3,696	3,934	4,765	5,899	6,482
Total current liabilities	8,097	21,861	27,281	30,796	23,455	20,984
Lease liability, non-current	8,366	7,353	5,883	4,545	6,729	5,648
Total liabilities	30,607	38,072	41,610	43,437	38,117	34,303
Retained earnings (accumulated deficit)	(11,457)	(20,120)	(25,621)	(20,027)	3,659	2,756
Total stockholders' equity	55,409	46,688	32,886	39,816	55,620	56,403
Total liabilities and equity	86,016	84,760	74,496	83,253	93,737	90,706
Common shares outstanding (cover page) thousands of shares	9,225	9,297	9,390	9,537	9,728	9,870

Fiscal years (FEIM's year ends in late April)

In thousands of dollars	FY 2021Apr 30, 2021	FY 2022Apr 30, 2022	FY 2023Apr 30, 2023	FY 2024Apr 30, 2024	FY 2025Apr 30, 2025	FY 2026Apr 30, 2026
Net income (loss)	680	(8,663)	(5,501)	5,594	23,686	(903)
Stock-based compensation	273	247	197	822	1,161	1,974
Depreciation and amortization	3,301	3,025	2,434	2,124	2,055	1,893
Net cash from operating activities	12,157	4,036	1,175	8,708	(1,428)	1,282
Purchases of property and equipment	1,239	1,860	918	1,492	1,808	2,859
Net cash from investing activities	(1,193)	(2,282)	8,667	(1,492)	(1,808)	(2,859)
Share repurchases	—	—	—	0	377	1,574
Dividends paid	—	0	9,354	0	9,567	0
Net cash from financing activities	(4,965)	0	(9,354)	0	(9,944)	(1,574)
Net change in cash	5,999	1,754	488	7,216	(13,180)	(3,151)

SIC 3825 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 3825 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Frequency Electronics	61,407	23,451	2,622	11.3M	—	Q1 FY27 10-QJul 31, 2026
Quanterix	44,169	32,906	(5,119)*	47.3M	18.3 quarters	Q2 FY26 10-QJun 30, 2026
Quantum-Si	23,653	344	(18,444)*	not reported	6.1 quarters	Q2 FY26 10-QJun 30, 2026
908 Devices	63,019	16,074	3,171*	41.3M	—	Q2 FY26 10-QJun 30, 2026
Alamar Biosciences	121,532	33,545	not reported	69.5M	—	Q3 FY26 10-QSep 30, 2026
Mesa Laboratories	30,695	60,138	14,736	5.6M	—	Q1 FY27 10-QJun 30, 2026
Pacific Biosciences of California	61,003	39,007	(35,583)*	310.8M	6.7 quarters	Q2 FY26 10-QJun 30, 2026
Senseonics Holdings	44,753	14,483	(30,138)*	52.9M	4.7 quarters	Q2 FY26 10-QJun 30, 2026
Cytek Biosciences	73,846	48,140	1,367*	130.0M	—	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.